Pharmaxis Revenue and Competitors
Estimated Revenue & Valuation
- Pharmaxis's estimated annual revenue is currently $18.7M per year.
- Pharmaxis's estimated revenue per employee is $201,000
Employee Data
- Pharmaxis has 93 Employees.
- Pharmaxis grew their employee count by 2% last year.
Pharmaxis Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $62.9M | 313 | 8% | N/A | N/A |
#2 | $26.5M | 132 | 7% | N/A | N/A |
#3 | $20.5M | 102 | 0% | N/A | N/A |
#4 | $18.3M | 91 | 6% | N/A | N/A |
#5 | $18.7M | 93 | 2% | N/A | N/A |
#6 | $72.2M | 359 | 6% | N/A | N/A |
#7 | $55.3M | 275 | 6% | N/A | N/A |
#8 | $35.8M | 178 | 6% | N/A | N/A |
#9 | $31M | 154 | 4% | N/A | N/A |
#10 | $70.8M | 352 | 5% | N/A | N/A |
What Is Pharmaxis?
Pharmaxis is a specialty pharmaceutical company involved in the research, development and commercialisation of new therapies for undertreated respiratory diseases. Our first product, Aridol, is now registered for sale in the United States, Europe, Australia and South East Asia. Aridol is designed to detect bronchial hyperresponsiveness and assist in the management of asthma. Our second product, Bronchitol, an Australian discovered and developed product which was approved for marketing in Australia in February 2011. In October 2011 Bronchitol received a positive opinion by a European regulatory committee, clearing the way for its marketing in 29 countries in Europe. We are committed to bringing our therapeutic advances for respiratory and immune diseases to patients throughout the world, and to building an internationally successful pharmaceutical business: one that's built to last. Undertreated Respiratory Diseases, Research and Development
keywords:N/A
N/A
Total Funding
93
Number of Employees
$18.7M
Revenue (est)
2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Pharmaxis's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Process Engineer | Reveal Email/Phone |
2 | Statistics Manager | Reveal Email/Phone |
3 | Facility Engineer | Reveal Email/Phone |
4 | Head Drug Discovery | Reveal Email/Phone |
5 | Quality Control Analyst | Reveal Email/Phone |
6 | Director | Reveal Email/Phone |
7 | Senior Research Scientist | Reveal Email/Phone |
8 | Research Scientist (Biology) | Reveal Email/Phone |
9 | Research Scientist | Reveal Email/Phone |
10 | CIO | Reveal Email/Phone |
Pharmaxis News
... And Forecast | Gilead Sciences, Aradigm, Lupin Ltd. Polyphor, Joincare Pharmaceutical Group, Pharmaxis Ltd and Savara Pharmaceuticals.
Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) is an Australian pharmaceutical research company developing drugs for inflammatory and fibrotic diseases,...
Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) is gearing up to present two research and development showcase webinars for its two lead drug discoveries -...
For personal use only PHARMAXIS LTD ABN 75 082 811 630 SHARE PURCHASE PLAN OFFER BOOKLET Thursday, 25 November 2021 Opening Date: Thursday, 25 November 2021 Closing Date: 5:00pm (Sydney, Australia time) on Wednesday, 15 December 2021 NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTL ...
SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at ...
Other Companies in Frenchs Forest
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | N/A | 153 | 43% | N/A |
#2 | $52.3M | 164 | 9% | N/A |
#3 | $44.7M | 179 | 5% | N/A |
#4 | $45.7M | 183 | 5% | N/A |
#5 | $49M | 212 | 7% | N/A |